Biden pro­pos­al on 'march-in' rights would have lim­it­ed ef­fect on cur­rent drug costs, crit­ics say

As the Biden ad­min­is­tra­tion rolls out new draft guid­ance around the use of march-in rights on high-priced drugs, some crit­ics ar­gue that the step is un­like­ly to have a near-term im­pact on drug pric­ing and could harm in­no­va­tion.

Un­der the Bayh-Dole Act of 1980, the gov­ern­ment can, in lim­it­ed cir­cum­stances, “march in” and is­sue new li­cens­es for cer­tain patents that were based on fed­er­al­ly-fund­ed re­search. The gov­ern­ment has nev­er ex­er­cised that au­thor­i­ty, and the frame­work re­leased Thurs­day is the first time that price has been con­sid­ered an ex­plic­it fac­tor in de­ter­min­ing whether march-in au­thor­i­ty is ap­pro­pri­ate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.